Sotatercept

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Sotatercept
Accession Number
DB12118  (DB05995)
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Fusion proteins
Description

Sotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
ACE-011
Categories
UNII
0QI90BTJ37
CAS number
1001080-50-7

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UActivin receptor type-2ANot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Sotatercept.
AbituzumabThe risk or severity of adverse effects can be increased when Sotatercept is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Sotatercept is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Sotatercept.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Sotatercept.
AducanumabThe risk or severity of adverse effects can be increased when Sotatercept is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Sotatercept.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sotatercept.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Sotatercept.
AmatuximabThe risk or severity of adverse effects can be increased when Sotatercept is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911284

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1, 2RecruitingTreatmentDiamond Blackfan Anemia1
2Active Not RecruitingTreatmentBeta Thalassemia Intermedia / Beta Thalassemia Major1
2Active Not RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
2CompletedTreatmentAnemias1
2CompletedTreatmentAnemias / Chronic Myelomonocytic Leukemia / Chronic Myelomonocytic Leukemia (CMML) / Low to Intermediate-1 MDS / Myelodysplastic Syndromes / Myelodysplastic Syndromes (MDS)1
2CompletedTreatmentAnemias / Chronic Renal Failure (CRF)1
2CompletedTreatmentMultiple Myeloma (MM)1
2RecruitingTreatmentAgnogenic Myeloid Metaplasia / Anemias / Leukemias / Myelodysplastic/Myeloproliferative Neoplasms1
2RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
2TerminatedSupportive CareAnemias / Bladder Cancers / Cancer of Head and Neck / Carcinoma, Small-Cell Lung / Lung Cancer Non-Small Cell Cancer (NSCLC) / Uterine Cervical Cancer1
2TerminatedSupportive CareTumors, Solid1
2TerminatedTreatmentChemotherapy Induced Anemia1
2WithdrawnSupportive CareMultiple Myeloma (MM)1
Not AvailableAvailableNot AvailableMyelodysplastic Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Transmembrane receptor protein serine/threonine kinase activity
Specific Function
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which auto...
Gene Name
ACVR2A
Uniprot ID
P27037
Uniprot Name
Activin receptor type-2A
Molecular Weight
57847.12 Da

Drug created on October 20, 2016 15:23 / Updated on December 02, 2019 09:18